IP Library › Granted Patent US 9,474,255
Granted Patent B2
US 9,474,255 · App. 14/681,617 · Granted Oct 25, 2016

Non-human animals having humanized Fc-gamma receptors

Inventors: Andrew J. Murphy (Croton-On-Hudson, NY); Lynn Macdonald (White Plains, NY); Cagan Gurer (Valhalla, NY); Karolina A. Meagher (Tarrytown, NY); Naxin Tu (Pleasantville, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A01K67/0278A01K2217/072A01K2227/105A01K2267/01A01K2267/0337A01K2267/0387C07K14/70535
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,474,255
App. No.
14/681,617
Granted
Oct 25, 2016
Kind
B2
Abstract

Genetically modified mice and methods and compositions for making and using the same are provided, wherein the genetic modification comprises humanization of an FcγRI protein.

Claims (23)

1. A mouse that expresses an FcγRI protein comprising an extracellular portion of a human FcγRI α chain and an intracellular portion of a mouse FcγRI α chain, wherein the FcγRI protein comprises an FcγRI α chain amino acid sequence at least 90% identical to SEQ ID NO: 5.

2. The mouse of claim 1 , wherein the extracellular portion of a human FcγRI α chain comprises an EC1 domain, EC2 domain, an EC3 domain, or a combination thereof.

3. The mouse of claim 2 , wherein the EC1 domain is encoded by an exon at least 90% identical to exon 3 of SEQ ID NO: 3.

4. The mouse of claim 2 , wherein the EC2 domain is encoded by an exon at least at 90% identical to exon 4 of SEQ ID NO: 3.

5. The mouse of claim 2 , wherein the EC3 domain is encoded by an exon at least 90% identical to exon 5 of SEQ ID NO: 3.

6. The mouse of claim 1 , wherein the mouse does not detectably express a full-length mouse FcγRI α chain.

7. The mouse of claim 1 , wherein the intracellular portion of an FcγRI α chain comprises a cytoplasmic domain of a mouse FcγRI α chain in whole or in part.

8. The mouse of claim 1 , wherein the FcγRI protein further comprises a mouse FcγRI α chain transmembrane domain in whole or in part.

9. The mouse of claim 1 , wherein the FcγRI protein comprises an FcγRI α chain amino acid sequence identical to SEQ ID NO: 5.

10. The mouse of claim 1 , wherein the FcγRI protein is expressed on monocytes, macrophages, neutrophils or dendritic cells.

11. The mouse of claim 10 , wherein the expression of the FcγRI protein is increased upon administration of murine granulocyte colony stimulating factor (mG-CSF) to the mouse.

12. An embryonic stem cell whose genome comprises a FcγRI gene that encodes an FcγRI α chain comprising an extracellular portion of a human FcγRI α chain and an intracellular portion of a mouse FcγRI α chain, wherein the FcγRI α chain comprises an amino acid sequence at least 90% identical to SEQ ID NO: 5.

13. The cell of claim 12 , wherein the FcγRI gene comprises exons 3, 4, and 5 of a human FcγRI gene.

14. The cell of claim 12 , wherein the FcγRI gene further comprises one or more human 5′ untranslated regions flanking human exon 1.

15. The cell of claim 12 , wherein the extracellular portion of the human FcγRI protein comprises one or more of EC1, EC2, and EC3.

16. The cell of claim 12 the FcγRI α chain comprises an amino acid sequence identical to SEQ ID NO: 5.

17. The cell of claim 12 , wherein the FcγRI gene comprises exon 6 of a mouse FcγRI gene.

18. The cell of claim 12 , wherein the intracellular portion of the mouse FcγRI protein comprises the cytoplasmic domain of a mouse FcγRI protein in whole or in part.

19. The cell of claim 12 , wherein the FcγRI gene is positioned at an endogenous FcγRI locus.

20. A mouse embryo generated from the embryonic stem of claim 12 .

21. A method of making a mouse that expresses FcγRI protein comprising an extracellular portion of a human FcγRI protein and an intracellular portion of a mouse FcγRI protein, the method comprising steps of:

(a) obtaining a mouse embryonic stem cell of claim 12 ; and

(b) creating a mouse using the embryonic cell of (a).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2016
From: MURPHY, ANDREW J.; MACDONALD, LYNN; GURER, CAGAN; MEAGHER, KAROLINA A.; TU, NAXIN
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 038291/0301 →
Continuity (2)
Provisional Application 61977037 · Apr 8, 2014
Related Publication 20150282463A1 · Oct 8, 2015